Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Active Not Recruiting Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs